SCHEMBL25826015

SCHEMBL25826015

Cc1cccc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccc(N6CC(F)(F)C6)cc45)nc3)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 8/20 0.45
DNMT3A Q9Y6K1 6/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
MAPKAPK2 P49137 1/20 0.42
DNMT3L Q9UJW3 4/20 0.42
EHMT1 Q9H9B1 2/20 0.42
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 1/20 0.41
RAB9A P51151 1/20 0.41
GAA P10253 1/20 0.41
MYC P01106 1/20 0.41
MAP2K3 P46734 1/20 0.41
EHMT2 Q96KQ7 1/20 0.41
DNMT3B Q9UBC3 1/20 0.41
USP2 O75604 1/20 0.41
MAPT P10636 1/20 0.41
MAPK14 Q16539 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23999697 0.91 KMT2A (0.44) DNMT1DNMT3AKMT2AMEN1MAPKAPK2
SCHEMBL30180438 0.91 KMT2A (0.44) DNMT1DNMT3AKMT2AMEN1MAPKAPK2
SCHEMBL25826014 0.91 MAPKAPK2 (0.47) DNMT1DNMT3AKMT2AMEN1MAPKAPK2
SCHEMBL30180641 0.85 KMT2A (0.42) DNMT1DNMT3AKMT2AMEN1MAPKAPK2
SCHEMBL23999846 0.85 KMT2A (0.42) DNMT1DNMT3AKMT2AMEN1MAPKAPK2
SCHEMBL30180612 0.83 MAPT (0.42) DNMT1DNMT3AKMT2AMEN1MAPKAPK2
SCHEMBL23999797 0.83 MAPT (0.42) DNMT1DNMT3AKMT2AMEN1MAPKAPK2
SCHEMBL25184667 0.83 USP2 (0.51) DNMT1DNMT3AKMT2AMAPKAPK2DNMT3L
SCHEMBL30180418 0.83 USP2 (0.51) DNMT1DNMT3AKMT2AMAPKAPK2DNMT3L
SCHEMBL23999440 0.81 MAPT (0.45) DNMT1DNMT3AKMT2AMEN1MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR DNMT1 4785/4885DNMT3A 4693/4885KMT2A 3974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.